The plasmid DNA manufacturing market size is expected to see exponential growth in the next few years. It will grow to $5.49 billion in 2028 at a compound annual growth rate (CAGR) of 23.7%. The anticipated growth in the forecast period can be attributed to several factors. These include the increasing use of plasmid DNA in the development of DNA vaccines for infectious diseases, the rising adoption of plasmid DNA in the development of antibody-drug conjugates and personalized therapies, the utilization of plasmid DNA in developing cancer treatments, and advancements in intellectual property developments related to plasmid DNA technologies. Major trends expected in the forecast period encompass increased activity in licensing agreements for plasmid DNA technologies, the provision of customized solutions, implementation of cost reduction strategies, utilization of high-throughput screening methods, and the development of scalable manufacturing solutions.
The increasing adoption of gene therapy is poised to drive the expansion of the plasmid DNA manufacturing market in the future. Gene therapy, a medical approach involving the modification or manipulation of genes to treat or prevent diseases, is gaining traction due to advancements in genetic engineering technologies, augmented investment in research and development, successful clinical trials, and the rising incidence of genetic disorders. These factors underscore its potential to offer long-lasting or permanent remedies. Plasmid DNA manufacturing plays a crucial role in gene therapy as it produces the vectors necessary to deliver therapeutic genes into cells, facilitating the treatment of genetic disorders. For instance, data from the American Society of Gene & Cell Therapy reveals a 10% increase in the number of gene therapies in Phase III clinical trials during Q3 2023, marking the first quarterly uptick since Q3 2022. Thus, the growing acceptance of gene therapy is fueling the growth of the plasmid DNA manufacturing market.
Key players in the plasmid DNA manufacturing market are focusing on the development of advanced bioprocessing technologies to enhance the efficiency, scalability, and quality of plasmid DNA production. These technological advancements aim to streamline manufacturing processes, reduce production costs, and ensure compliance with stringent regulatory standards for therapeutic applications. For example, Charles River Laboratories, a US-based pharmaceutical company, introduced the eXpDNA platform in January 2023. This platform integrates advanced bioprocessing technologies, scalable production methods, and stringent quality control measures to deliver high-quality plasmid DNA suitable for therapeutic and clinical applications. Widely utilized in gene therapy, DNA vaccine development, and other biopharmaceutical applications, the eXpDNA platform ensures high yield, purity, and consistency.
In August 2021, Danaher Corporation, a US-based medical equipment manufacturing company, completed the acquisition of Aldevron for $9.6 billion. This strategic acquisition bolsters Danaher's presence in the biotechnology sector by providing access to Aldevron's expertise in genetic material production. Through this acquisition, Danaher aims to support the advancement of genetic treatments and bolster research endeavors within the biotechnology industry, contributing to the development of therapies across diverse applications. Aldevron, a US-based biotechnology company specializing in plasmid DNA, mRNA, and protein manufacturing, enhances Danaher's capabilities in the burgeoning field of gene therapy.
Major companies operating in the plasmid dna manufacturing market are Thermo Fisher Scientific Inc., Eurofins Genomics LLC, Catalent Inc., Charles River Laboratories, Recipharm AB, Kaneka Corp., Genscript Biotech Corporation, Aldevron LLC, Genewiz, OriGene Technologies, Celonic AG, Creative Biogene, Cellectis, Synbio Technologies, VectorBuilder Inc., Altogen Biosystems, Addgene, Andelyn Biosciences, AGC Biologics, VGXI, BioCat GmbH, GeneCopoeia, PlasmidFactory GmbH & Co. KG, Akron Biotech, PackGene Biotech lnc.
North America was the largest region in the plasmid DNA manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasmid dna manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the plasmid dna manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Plasmid deoxyribonucleic acid (DNA) manufacturing involves producing large quantities of plasmid DNA molecules for various biotechnological applications, including gene therapy, molecular cloning, and recombinant protein production. This process entails cultivating bacterial cells containing the desired plasmid DNA, followed by purification to isolate the plasmid DNA from other cellular components.
The primary grades of plasmid DNA manufacturing include research and development grade, and good manufacturing practice (GMP) grade. Research and Development grade plasmid DNA is primarily intended for laboratory research and early-stage development processes. It is utilized across various development phases such as pre-clinical therapeutics, clinical therapeutics, and marketed therapeutics for treating infectious diseases, cancer, genetic disorders, and other ailments. This type of DNA is essential for various applications including DNA vaccines, cell and gene therapy, immunotherapy, and others.
The plasmid DNA manufacturing market research report is one of a series of new reports that provides plasmid DNA manufacturing market statistics, including the plasmid DNA manufacturing industry global market size, regional shares, competitors with plasmid DNA manufacturing market share, detailed plasmid DNA manufacturing market segments, market trends, and opportunities, and any further data you may need to thrive in the plasmid DNA manufacturing industry. This plasmid DNA manufacturing market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The plasmid DNA manufacturing market consists of revenues earned by entities by providing services such as plasmid design, construction, production, purification, quality control, customization, storage, shipping, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The plasmid DNA manufacturing market also includes sales of bioreactors, centrifuges, incubators, chromatography systems, freeze dryers, electrophoresis systems, and microscopes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
Executive Summary
Plasmid DNA Manufacturing Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on plasmid DNA manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for plasmid DNA manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The plasmid DNA manufacturing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Grade: Research And Development Grade; Good Manufacturing Practice (GMP) Grade2) By Development Phase: Pre-Clinical Therapeutics; Clinical Therapeutics; Marketed Therapeutics
3) By Disease: Infectious Disease; Cancer; Genetic Disorder; Other Diseases
4) By Application: Deoxyribonucleic Acid (DNA) Vaccines; Cell And Gene Therapy; Immunotherapy; Other Applications
Key Companies Mentioned: Thermo Fisher Scientific Inc.; Eurofins Genomics LLC; Catalent Inc.; Charles River Laboratories; Recipharm AB
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Eurofins Genomics LLC
- Catalent Inc.
- Charles River Laboratories
- Recipharm AB
- Kaneka Corp.
- Genscript Biotech Corporation
- Aldevron LLC
- Genewiz
- OriGene Technologies
- Celonic AG
- Creative Biogene
- Cellectis
- Synbio Technologies
- VectorBuilder Inc.
- Altogen Biosystems
- Addgene
- Andelyn Biosciences
- AGC Biologics
- VGXI
- BioCat GmbH
- GeneCopoeia
- PlasmidFactory GmbH & Co. KG
- Akron Biotech
- PackGene Biotech lnc.